MRX-5
Mycobacterium abscessus Pulmonary Disease (NTM Infection)
Phase 2Active
Key Facts
Indication
Mycobacterium abscessus Pulmonary Disease (NTM Infection)
Phase
Phase 2
Status
Active
Company
About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a clinical-stage biotech company pioneering novel antibiotics to combat the global crisis of antimicrobial resistance (AMR). Its pipeline is led by late-stage candidates targeting multidrug-resistant Gram-positive bacteria like MRSA and novel programs against challenging Gram-negative and non-tuberculous mycobacterial (NTM) infections. With a dual operational base in China and the U.S., the company is strategically positioned to address critical public health threats in major markets while navigating the complex development and commercial pathways for anti-infectives.
View full company profile